Health & Biotech
Health & Biotech
Dimerix hits key milestone in Europe with first regulatory approval for its Phase 3 FSGS study, shares jump
Health & Biotech
Creso Pharma takes cannabis into the metaverse, creating Creso verse on The Sandbox
Health & Biotech
Exopharm and Astellas team up for exosomes evaluation
Health & Biotech
EZZ’s big growth plans on target after another quarter, oodles of cash and expanding distribution
Health & Biotech
Never looked better: Volpara Q3 cash receipts up, ARR beats record, powerful on key metrics
Health & Biotech
Intelicare announces another record quarter with a 55% rise in sales
Health & Biotech
Prescient is well funded as it looks to bring its novel OmniCAR T-cell therapy into clinical trials
Health & Biotech
New brand launches and an innovative inventory has Wellnex Life Top Gun in ‘22
Health & Biotech
PharmAust pushes forward with lead drug monepantel, four clinical trials to rollout
Health & Biotech
With a big year ahead, excitement is building for Dimerix’s global COVID-19 studies where results are due this quarter
Health & Biotech
Opin season arrives for patients as AI drives Opyl boom in Q2 receipts
Health & Biotech
ECS Botanics doesn’t miss a beat with more strong revenue growth as momentum continues to build
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.